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Abstract:  HIV-1 reverse transcriptase (RT) inhibitors currently used in antiretroviral 
therapy can be divided into two classes: (i) nucleoside analog RT inhibitors (NRTIs), which 
compete with natural nucleoside substrates and act as terminators of proviral DNA 
synthesis, and (ii) non-nucleoside RT inhibitors (NNRTIs), which bind to a hydrophobic 
pocket close to the RT active site. In spite of the efficiency of NRTIs and NNRTIs, the rapid 
emergence of multidrug-resistant mutations requires the development of new RT inhibitors 
with an alternative mechanism of action. Recently, several studies reported the discovery of 
novel non-nucleoside inhibitors with a distinct mechanism of action. Unlike classical 
NNRTIs, they compete with the nucleotide substrate, thus forming a new class of RT 
inhibitors: nucleotide-competing RT inhibitors (NcRTIs). In this review, we discuss current 
progress in the understanding of the peculiar behavior of these compounds. 
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1. Introduction 
Current treatments against human immunodeficiency virus type 1 (HIV-1) infections include six 
different classes of drugs, targeting  the three viral enzymes (more than 20 different compounds in 
clinical use target the protease, reverse transcriptase and integrase), the virus fusion process 
(enfuvirtide/T-20 targets the viral gp41) or viral entry (maraviroc targets the human CCR5 cellular 
coreceptors) [1]. Combinations of these drugs are used in a treatment strategy known as HAART 
(highly active antiretroviral therapy). The viral reverse transcriptase (RT) was identified early as an 
interesting target, with the use of zidovudine (AZT) [2] approved for the treatment of HIV-1 infections 
in 1987. In spite of more than 20 years of developments, RT remains an important target in 
antiretroviral therapy, since 12 out of 25 individual agents licensed for the treatment of HIV-1 
infection target its polymerization active site.  
Currently, approved RT inhibitors are divided into two classes: eight nucleoside and nucleotide RT 
inhibitors (NRTIs), and four non-nucleoside RT inhibitors (NNRTIs). NRTIs are phosphorylated by 
cellular enzymes and converted into their active NRTI triphosphate form. Once activated, they 
compete with the natural nucleoside triphosphate (dNTP) for binding the RT polymerase active site, 
and after their incorporation into the primer strand, act as terminator of DNA synthesis due to the lack 
of a 3’-hydroxyl group [3]. In contrast, NNRTIs comprise a structurally diverse family of compounds 
all binding the same hydrophobic pocket (non-nucleoside inhibitor binding pocket, NNIBP) located in 
the palm domain of the p66 subunit and about 10 Å from the polymerase catalytic site [4–7]. Upon 
binding the HIV-1 RT, NNRTIs do not interfere with dNTP binding, but rather lead to unproductive 
complexes by altering the conformation or mobility of RT, thereby exerting a non-competitive 
inhibition [8–10]. In addition, whereas NRTIs are characterized by a rather large antiviral spectrum on 
several Lentiviridae species, NNRTIs are highly specific for HIV-1 RT and result in less adverse 
effects than NRTIs. 
New strategies to inhibit RT enzymatic activities and to overcome viral resistance are still under 
investigation. A successful example is illustrated by the recent development of the very promising 
“next-generation” NNRTIs developed by Tibotec, namely etravirine (TMC125, ETV) [11,12] that has 
been approved for HIV-1 treatment in 2008, and the rilpivirine (TMC278) [13,14] that is currently in 
Phase III clinical trials [15,16]. However, long-term treatment of HIV-1 by antiretrovirals is prevented 
by incomplete viral suppression resulting from the rapid emergence of drug-resistant mutants. Since 
NRTIs and NNRTIs target different binding sites and are using distinct inhibition mechanisms, the 
mechanism of resistance is specific for each class of inhibitor and leads to the selection of completely 
different sets of resistance mutations: whereas NRTI-associated mutations have a rather broad spatial 
distribution in the neighborhood of the nucleotide substrate binding site, NNRTI-resistance mutations 
are concentrated in the NNIBP (Figure 1).  
NNRTIs have become a cornerstone of HAART. However, in spite of the remarkable potency of 
currently marketed NNRTIs, the rapid selection of single mutations can confer resistance to most 
NNRTIs, leading to an almost complete loss of their activity, without significantly affecting the viral 
infectivity. Consequently, there is an urgent need for the development of new RT inhibitors with an 
alternative mechanism of action and exhibiting different resistance profiles. Viruses 2010, 2                  
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Figure 1. Localization of more frequent NNRTI- and NRTI-associated resistance 
mutations on the RT/primer-template complex [17]. NNRTI-selected mutations (in blue) 
are all localized in the NNIBP, whereas NRTI-selected mutations (in green) are distributed 
around the dNTP binding site. The template strand is shown in yellow, while the growing 
complementary DNA chain is in orange. The catalytic D110, D185 and D186 are shown in 
red, the two magnesium cations required for the catalytic reaction as yellow spheres, and 
the incoming nucleotide is represented in space filling mode. 
 
 
For this purpose, several RNaseH inhibitors targeting the two metal ions essential for this RT 
activity have already been developed [18–21]. These compounds are, however, so far lacking antiviral 
activity. In 2006, the indolopyridones were discovered almost concurrently by two groups [22,23] and 
led to the identification of a new class of RT inhibitors targeting the polymerization activity of the RT, 
but with a mechanism of action that involves a competitive binding with the incoming dNTP. Only a 
few months later, another family of non-nucleoside compounds, the 4-dimethylamino-6-
vinylpyrimidines (DAVPs), was reported to inhibit the RT polymerase activity also by a competitive 
mechanism with the nucleotide substrate and distinct from those of common NNRTIs [24]. Because 
their original mechanism of action is competitive with the nucleotide substrate - although they are not 
chemically-related to NRTIs - it was proposed to refer to members of this class of compounds as 
“nucleotide-competing RT inhibitors” (NcRTIs) [25]. This review focuses on progress over the past 
three years in understanding the mechanism of action of this new family of RT inhibitors.  
2. Indolopyridones (INDOPYs) 
The indolopyridones VRX-329747 {1-(4-nitrophenyl)-2-oxo-2,5-dihydro-1H-pyrido[3,2-b]indole-
3-carbonitrile} and VRX-413638 (or INDOPY-1) {5-methyl-1-(4-nitrophenyl)-2-oxo-2,5-dihydro-1H-Viruses 2010, 2                  
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pyrido[3,2-b]indole-3-carbonitrile} were identified during cell-based high-throughput screenings of 
Valeant and Tibotec compound libraries aimed at identifying new HIV-1 inhibitors that were effective 
against drug-resistant mutants, possibly with a new mechanism of action [22, 23]. These two 
compounds emerged as potent HIV-1 inhibitors (EC50 = 150-200 nM for VRX-329747 and   
EC50 = 20-30 nM for INDOPY-1) with a low cellular toxicity (CC50 > 100 µM). In vitro enzymatic 
experiments based on inhibition of DNA synthesis led to the conclusion that both compounds were 
targeting the reverse transcription step of HIV-1 replication. In spite of their non-nucleosidic chemical 
structure (Figure 2), several features of indolopyridones (INDOPYs) were clearly inconsistent with 
their classification as NNRTIs, thus calling for more investigations of their mechanism of action. 
Figure 2. Chemical structures of indolopyridones. 
 
 
A first striking feature of INDOPYs is their antiviral spectrum, which is clearly distinct from that of 
NNRTIs and NRTIs. Whereas NNRTIs are highly specific for HIV-1, INDOPY-1 remains active on 
HIV-2 (EC50 = 180 nM on HIV-2 ROD) and SIV (EC50 = 210 nM on SIV Mac251) [22]. However, the 
antiviral activity of INDOPY-1 seems restricted to lentiviruses since no inhibition was reported on 
other retroviruses like Moloney murine sarcoma virus (Mo-MSV) [22], thus contrasting with the broad 
antiretroviral spectrum of NRTIs that do not markedly discriminate between RTs from different 
origins and even recognize the DNA polymerase of human hepatitis B virus. 
Another important feature of INDOPYs is their unique activity profile towards drug-resistant RT 
mutants. Antiviral tests conducted on HIV-1 molecular clones revealed that VRX-329747 and 
INDOPY-1 are not, or are only moderately, affected by several representative NNRTI-selected 
mutations, with a maximum of ~4-fold decrease of the EC50 towards the double K103N-L100I RT 
mutant [23]. This behavior contrasts with that of efavirenz (EFZ), which is dramatically affected by 
these mutations (Figure 3), with a complete loss of its antiviral activity (more than 100-fold change) 
for most of the tested mutants.  
In addition to this high activity on NNRTI-resistant strains, INDOPYs also revealed an unusual 
activity profile against NRTI-associated mutations. While INDOPY-1 is not affected by thymidine 
analog resistance mutations (TAMs, including M41L/L210W/T215Y and D67N/K70R/T215F/K219Q 
mutations [26–28]) or other frequent NRTI-induced mutations, its activity is moderately reduced by 
M184V or Y115F mutations (3- to 8-fold reduced activity) and strongly reduced by the combination of 
these two mutations (more than 100-fold change) [22,23]. On the contrary, hypersusceptibility was 
observed for viruses carrying the K65R mutation (2- to 5-fold increased activity) [22,23]. Noticeably, 
the K65R mutation causes reduced efficiency of all NRTIs, with the exception of zidovudine (AZT) [29].  Viruses 2010, 2                  
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Regarding mutations selected by viruses cultured in the presence of INDOPYs, it was found that 
four NRTI-resistance mutations were selected after six months of VRX-329747 selection [23]: 
M184V, a well-characterized mutation associated with a strong resistance to lamivudine (3TC) and 
emtricitabine (FTC); M41L, which strongly reduces susceptibility to stavudine (D4T) and AZT; A62V 
and V118I, two accessory mutations occurring with TAMs, the Q151M multi-dideoxynucleoside-
resistance mutation or the 69 insertions [30–32] and associated with subtle reductions in susceptibility 
to multiple NRTIs. Together with these four NRTI-associated mutations, two new mutations were 
found: S68N and G112S. All these mutations are located around the incoming nucleotide binding site, 
which is consistent with a new mechanism of action for VRX-329747 compared to NNRTIs. 
Figure 3. Activity profile of the indolopyridones VRX-329747 (green) and INDOPY-1 
(red) compared to efavirenz (blue) on HIV-1 molecular clones carrying NNRTI-selected 
mutations. The mean fold change is relative to the wild-type EC50. Adapted from [23]. 
 
 
In view of this remarkable resistance profile, in vitro experiments have been carried out on 
INDOPY-1 to provide more insight into its mode of inhibition of proviral DNA synthesis [22]. 
Detailed analysis of the DNA polymerization products in the presence of INDOPY-1 showed that the 
inhibitory mechanism was not affected by the identity of the incoming nucleotide, being competitive 
towards all four dNTPs. Moreover, these studies revealed that the inhibition was not resulting from 
chain termination, as it is the case for NRTIs, and was reversible. However, equilibrium-binding 
experiments showed that INDOPY-1 was able to bind and stabilize the binary complex of RT with its 
DNA template.  
Interestingly, the binding of INDOPY-1 was affected by the identity of the last nucleotide at the  
3'-end of the primer strand, with T and C being the most efficient in promoting INDOPY-1 binding. 
These data clearly indicated that INDOPY-1 preferentially binds to RT after the incorporation of 
pyrimidines. Similarly to all RNA and DNA polymerases, HIV-1 RT also undergoes a translocation 
step after nucleotide incorporation, exposing the next template position to its active site ready to accept Viruses 2010, 2                  
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the incoming nucleotide. Site-specific footprinting showed that INDOPY-1 binds to HIV-1 RT in its 
post-translocation conformation, in place of a nucleotide, and then induces a stable dead-end complex. 
Thus, the inhibition of HIV-1 RT by INDOPY-1 is due to a "freezed" conformation at the post-
translocation step, which prevents nucleotide binding [22]. In order to resume synthesis, INDOPY-1 
must dissociate from RT, an event which eventually occurs, albeit with slow kinetics. 
To investigate the correlation between phenotypic susceptibility to INDOPY-1 and the enzymatic 
properties of RT, a detailed analysis on mutants affecting the activity of the inhibitor in cell-based 
assays was also performed in vitro [25] (Figure 4). These studies revealed that mutations M184V and 
Y115F both induced a 2-fold increase of IC50 values for INDOPY-1, with a reduction of the enzyme 
pausing. A cumulative effect was observed on the double M184V/Y115F mutant, with a >15-fold 
increase in IC50. The synergic effect of these two mutations might be attributed to differences in 
inhibitor binding: whereas the M184V mutation reduces INDOPY-1 affinity (~6-fold change), the 
Y115F mutation mostly results in an increased binding of the natural nucleotide substrate (~3-fold 
increase in affinity). However, none of these mutations affect the aforementioned sequence specificity 
of INDOPY-1. On the contrary to M184V and Y115F mutations, the inhibitory effect of INDOPY-1 
was slightly increased in presence of the K65R mutation that reduces the affinity of the nucleotide 
substrate (~2-fold change) and increases the INDOPY-1 binding (1.6-fold change). This likely 
accounts for the observed hypersusceptibility of this RT mutant towards INDOPY-1. Taken together, 
these results are therefore in good agreement with cell-based assays [22]. Binding of INDOPY-1 was 
also investigated in vitro on the F61A mutant. This replication-defective RT mutant is characterized by 
an increased fidelity corroborated by a reduction in sensitivity to dideoxy-thymidine analogs and 
shows defects in nucleotide binding, but not in primer-template binding [33–35]. It was shown that the 
F61A mutation strongly enhances the IC50 value (>40-fold change) of INDOPY-1. In addition, 
whereas no stable ternary complex could be observed with the natural nucleotide substrate, a stable 
F61A RT/primer-template/INDOPY-1 complex can be formed [25], thus indicating that a decrease of 
the nucleotide binding can be sufficient to increase the INDOPY-1 inhibitory effect. 
Finally, the latter study also examined the effect on INDOPY-1 binding of abasic sites in the 
template strand at positions opposite the 3’-end of the primer (n) and the incoming nucleotide substrate 
(n + 1) (Figure 4). It was found that an abasic site at position n completely abolishes binding of 
INDOPY-1, whereas a modification of the n + 1 position did not significantly affect the binding [25]. 
This suggests that interactions with the 3’-end of the primer - likely stacking interactions with the 
nucleotide base - are a prerequisite for INDOPY-1 binding, while interactions with the nucleotide 
opposite the incoming dNTP – presumably hydrogen bonds with the base – are dispensable. These 
findings also well correlate with the marked preference of INDOPY-1 for pyrimidines residue at the 
3’-end of the primer, which also suggests a predominant role of stacking interactions with this position. Viruses 2010, 2                  
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Figure 4. Four different views showing the local environment around the HIV-1 RT 
polymerase active site and the putative INDOPY-1 binding site. The structure of the 
trapped RT/primer-template/incoming dNTP catalytic complex  [17] is represented. The 
three catalytic aspartic acids are shown as red sticks, the two required magnesium ions as 
yellow spheres, the DNA template in light yellow (positions n, n + 1 and n + 2 are labeled) 
and the DNA primer in orange. Residues affecting the inhibitory effect of INDOPY-1 
(F61, K65, Y115 and M184) and the incoming dTTP are also shown as sticks. The solvent 
accessible surface of the dTTP is shown in orange transparency. Adapted from [25]. 
 
 
3. 4-Dimethylamino-6-vinylpyrimidines (DAVPs) 
Independently from INDOPYs, the development of a straightforward combinatorial approach for 
the synthesis of 6-vinylpyrimidine derivatives [36] led to the discovery of a new family of RT 
inhibitors, the 4-dimethylamino-6-vinylpyrimidines (DAVPs, Figure 5) [24,37]. Because DAVPs are 
structurally related to the non-nucleoside RT inhibitor TNK-651 [38], an analog of the   
1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) family of NNRTIs (Figure 5), it was 
initially expected that they would also behave as NNRTIs. However, subsequent enzymological 
studies performed on DAVPs 1-3 revealed a competitive inhibition mechanism with the incoming 
nucleotide substrate reminiscent of those of INDOPYs and consistent with the classification of these 
compounds as NcRTIs [24,37]. Viruses 2010, 2                  
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Figure 5. Chemical structures of DAVP derivatives and of the reference compound TNK-651. 
 
Out of these three compounds, DAVP-1 emerged as the most active one on the wild-type enzyme 
(Ki = 8 nM) in cell-free assays [24]. However, whereas no significant loss of activity was observed in 
vitro on L100I or V179D (Ki = 12 and 15 nM, respectively) mutants, the affinity of the compound is 
severely affected by K103N and Y181I mutations (Ki = 3.2 and 39 µM, respectively). This activity 
profile thus differs from that of INDOPYs, which are unaffected by these mutations, and from licensed 
NNRTIs (Figure 6) since L100I and V179D mutations both strongly affect the inhibitory effect of 
efavirenz, nevirapine (NVP) and delavirdine (DLV) in vitro [39–41] and in cell-based assays [42]. In 
addition, these two mutations belong to the etravirine (ETV) resistance-associated mutations [43,44], 
causing moderate resistance to this drug [42, 45]. 
In view of this unusual resistance profile and to determine their mechanism of inhibition, in vitro 
reverse transcriptase titrations assays have been carried out on DAVPs in presence of increasing 
concentrations of either a RNA/DNA nucleic acid or the nucleotide substrates. These experiments 
revealed that the inhibition of the HIV-1 RT by DAVPs was sensitive to the nucleotide concentration, 
resulting in an increase in the apparent Km for dTTP, but not to the nucleic acid concentration [24]. 
The reference compound TNK-651 used as a comparison showed a typical non-competitive 
mechanism with respect to the nucleotide substrate (no significant variation of Km value for dTTP), 
indicating that the inhibitor binds independently from the natural substrate, as expected for a NNRTI. 
Figure 6. Comparative resistance profiles of Efavirenz (EFZ), Nevirapine (NVP), 
Delavirdine (DLV), Etravirine (ETR) and DAVP-1 towards four NNRTI-associated RT 
mutants. Red squares stand for strong loss of activity (>5-fold change), orange for 
intermediate loss of activity and green for weak loss of activity (<2-fold change). 
  K103N Y181I  L100I V179D 
DAVP-1             
EFV             
NVP             
DLV             
ETR             
Further insight into the mechanism of DAVP binding to the HIV-1 RT was provided by steady-state 
kinetic enzymatic studies performed with DAVP-1 on various RT/substrate complexes: the free 
enzyme, the RT/primer-template binary complex and the RT/primer-template/incoming nucleotide 
ternary complex (Table 1). These experiments showed that DAVP-1 is able to bind with the same Viruses 2010, 2                  
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affinity (Ki = 8 nM) to the unliganded RT and the RT/primer-template binary complex. However, 
although the equilibrium dissociation constant (Ki = koff/kon) are equivalent, a 13-fold faster 
association and 8-fold slower dissociation rate for the binary RT-primer/template complex are 
obtained with respect to the free RT [37]. This is in contrast with INDOPY-1, which is highly specific 
for the RT/primer-template complex since no binding was detected to the unliganded RT [23]. 
Regarding the catalytically competent ternary complex with both the primer-template and the 
nucleotide substrate, a 140-fold decrease of the association rate relating to the binary complex was 
observed, but no significant change in the dissociation rate [37]. As a result from these kinetic studies, 
it therefore appears that the binding of DAVP-1 to the free enzyme or to the RT/primer-template 
binary complex is more stable than to the RT/primer-template/dNTP complex. This peculiar behavior 
excludes a classical competitive inhibition mechanism for DAVPs, resulting only from a binding of the 
inhibitor to the polymerase catalytic site of the binary complex, as for NRTIs. Finally, although DAVP-1 
was shown to be highly active in cell-free assays, its antiviral efficiency remains to be tested in   
cell-based assays.  
Table 1. Kinetics of binding of DAVP-1 to different wild-type RT-substrate complexes 
(adapted from [37]). 
 K i (nM)  kon (M
−1 s
−1)
a koff (M
−1 s
−1)
b
Free RT  8  1.04 × 10
4  8.4 × 10
−5 
RT-primer/template  8  14 × 10
4  1.1 × 10
−5 
RT-primer/template-dNTP  16  0.1 × 10
4  1.6 × 10
−5 
a Calculated from kapp = kon•(Ki + [I]); 
bCalculated from koff = Ki•kon 
 
4. Structural Biology Studies of NcRTIs 
Structural biology studies are currently in progress for providing a detailed molecular view of how 
NcRTIs are interacting with the HIV-1 RT. X-ray crystallography already contributed precious and 
highly detailed information of NNRTIs bound to the free RT (see for instance [5, 6, 7]), thus helping 
for the development of the second generation of this class of inhibitors [13, 46]. However, at variance 
with NNRTIs that were successfully co-crystallized with the free RT, attempts to co-crystallize 
INDOPY-1 with the unliganded RT failed [23], likely because it is highly specific for the binary 
RT/primer-template complex. Unlike INDOPY-1, DAVPs bind the unliganded RT in addition to the 
binary complex and DAVP-1 was successfully co-crystallized with the RT in absence of nucleic   
acids [47]. Obtained crystals revealed a novel crystal packing differing from previously-reported   
RT structures.  
The structure of the wild-type HIV-1 RT/DAVP-1 complex revealed that the inhibitor does not bind 
the NNIBP, but rather at a novel site located in a hinge region at the interface between the p66 thumb 
and p66 palm subdomains, near the polymerase active site (Figure 7 and 8). Most of the residues 
interacting with the drug belong to an extremely conserved region of the HIV-1 RT from naïve and 
drug-treated patients [48], suggesting that amino acids forming the DAVP-1 binding site are not prone 
to mutations. In addition, the drug binding site includes several essential residues for the enzyme Viruses 2010, 2                  
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activity (Figure 8, right). Firstly, M230 and G231 are two critical residues that belong to the DNA 
primer grip [49], a highly conserved structural motif [50] comprising the p66 12-13 hairpin in 
HIV-1 RT [51] that helps the positioning of the 3’-hydroxyl end of the primer strand in the polymerase 
active site (and also involved through residues F227, W229, L234 into NNRTI binding [52]). 
Secondly, G262, K263 and W266 are located in the core of the H helix within the “helix clamp”, a 
motif involved into the primer-template recognition [53]. These residues belong to the minor groove 
binding track (MGBT) and play an essential role in nucleic acid binding by acting as “protein sensors” 
of the DNA minor groove [54–56]. Finally, M184 and D186, which are lying within 3.5–4.0 Å from 
the diethylamino group of DAVP-1, are part of the catalytically crucial YXDD motif (Y183MDD186 in 
HIV-1 RT). This motif is highly conserved among retroviruses [57, 58]: residue D186 is one of the 
three catalytic aspartic acids binding the two divalent magnesium cations required for the 
polymerization reaction [59], whereas M184 is likely involved into the fidelity of DNA synthesis [60] 
through interactions with the 3’-end of the primer and the incoming dNTP [17]. This latter residue is 
the only one, among those contacting DAVP-1, which has been reported to mutate as a result of 
antiviral drug pressure since the M184V/I substitution is responsible for high level resistance towards 
the NRTI lamivudine (3TC). 
Figure 7. Overall view of the HIV-1 RT/DAVP-1 complex showing the relative position 
of binding sites for NNRTI (circled in blue, important residues of the NNIBP are shown as 
blue sticks) and NRTI (circled in red, the three catalytic D110, D185 and D186 residues 
are represented as red sticks). The p51 subunit is represented in grey whereas p66 
subdomains are color-coded: fingers in yellow, thumb in orange, palm in light blue, 
connection in green and RNAseH in purple. The electron density map at 2.8 Å resolution is 
represented around DAVP-1. Residue W266 is also shown as sticks. Adapted from [47]. 
 
 
Another feature of the HIV-1 RT/DAVP-1 complex is the conformation adopted by the protein 
upon drug binding. In RT/NNRTI complexes, the RT undergoes a large structural rearrangement and 
adopts conformation similar to the one observed when the RT is bound to a DNA primer-template  
(see [61] for a complete review). In the RT/DAVP-1 complex on the contrary, the p66 thumb 
subdomain is folded into the DNA-binding cleft, similarly to the conformation reported in unliganded Viruses 2010, 2                  
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wild-type or drug-resistant RTs [62–64], or in drug-resistant RT bound to ATP [65] (high-resolution 
structures of unliganded RTs obtained after removal of inhibitor from RT/NNRTI co-crystals [4,66] 
were not used for comparison since the conformation of the protein is “frozen” by the crystal packing). 
However, some slight differences are observed compared to the latter structures: a ~3.0 Å translation 
of the whole p66 thumb subdomain towards the p66 palm subdomain follows the DAVP-1 binding 
(Figure 9). The movement is likely initiated by a steric hindrance between the inhibitor and the 12-
13 hairpin (M230 and G231) and is propagated to the p66 thumb subdomain. 
Figure 8. Left: Detailed view of the HIV-1 RT/DAVP-1 complex showing the electron 
density map at 2.8 Å resolution (in blue) around DAVP-1 and residues D110, M184, 
D185, D186 and W266. Right: Detailed view of the inhibitor binding pocket. Water 
molecules are shown as red spheres. Hydrogen bonds are represented with black dotted 
lines. Adapted from [47]. 
 
 
This crystal structure therefore reveals that the binding site of DAVP-1 is located in a region critical 
for the correct positioning of the 3'-OH primer for the in-line nucleophilic attack by the incoming 
dNTP and the subsequent chemical bond formation with its -phosphate. It is known that mutations of 
residues involved in the stabilization of the primer/template junction can reduce the binding affinity 
for the incoming dNTP, as is the case for the L74 residue, which contacts the template at position n + 1 
and whose substitution with a valine is responsible for NRTIs resistance [67,68]. Thus, it is likely that 
the DAVP-1 binding causes a misplacement of the primer, so that the ternary complex formed with the 
incoming dNTP does not undergo to the "open-to-close" conformational transition required to stabilize 
the dNTP within the active site, resulting in lack of nucleotide incorporation. This mechanism, which 
therefore differs from the putative mechanism of action of INDOPYs, is also consistent with the kinetic 
data, suggesting that in the ternary complex conformation (i.e., in the presence of a stably bound 
dNTP), binding of DAVP-1 is unfavored [24]. The peculiar resistance profile observed for DAVP-1 
suggests that it gains access to its novel binding site not through the same route of the incoming 
dNTPs, but using structural elements in common with the NNIBP [47]. In this respect, it has to be Viruses 2010, 2                  
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mentioned that the Y181 residue is located on the same structural element of the catalytic D185 and 
D186 and that its mutation (as in the case of the Y181I substitution) can induce resistance to NRTIs [69]. 
This RT/DAVP-1 complex, obtained without nucleic acids, obviously does not completely clarify 
the competitive mechanism of inhibition of DAVPs, but provides first structural requirements for 
binding of DAVP-1 to the free RT and for understanding the original inhibition mechanism of this 
compound. Consequently, ongoing research in our group includes structural studies of a challenging 
RT/primer-template/NcRTI ternary complex, which would provide more valuable information about 
NcRTI binding and mechanism of inhibition. To prevent the dissociation of the RT/DNA complex and 
to trap a covalent stable and homogenous complex, a disulfide cross-linking strategy that has already 
been successfully used in several X-ray studies [17,70–73] is used for co-crystallization of RT/primer-
template complex with DAVP-1 or INDOPY-1 (Gerard et al., unpublished results).  
Figure 9. Detailed view of the DAVP-1 binding pocket showing a superposition of the c 
backbone in unliganded HIV-1 RT structures (in grey, PDB 1DLO, 1QE1 and 1HQE) and 
in RT bound to DAVP-1 (in orange, PDB 3ITH and 3ISN). Residues W266, D110, D185 
and D186 are shown in yellow in unliganded RT structures and in red in the   
RT/DAVP-1 complex. 
 
 
5. Conclusions 
The development of INDOPYs and DAVPs led to the identification of “Nucleotide-competing RT 
Inhibitors” (NcRTIs), a new class of RT Inhibitors endowed with a novel mechanism of action. 
Although they are structurally distinct from NRTIs, NcRTIs also bind close to the RT polymerase 
active site (Figure 4) and compete with the natural nucleotide substrate (Figure 10). However, because 
NcRTIs (especially INDOPYs) exhibit a resistance profile distinct from NNRTIs and NRTIs - with the 
exception of the M184V mutation that dramatically affects FTC and 3TC susceptibility, but only Viruses 2010, 2                  
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moderately INDOPY-1 - they can be potentially used both in naïve and in treatment-experienced 
patients or combined with classic RT inhibitors, accounting for more exploration of this new class of 
inhibitors. Further ongoing developments in structural biology include the structure determination of 
NcRTIs in complex with the RT bound to a DNA primer-template complex, which is clearly required 
for a better understanding of their mechanism of action and for helping in the design of improved 
compounds. Finally, the discovery of NcRTIs nicely illustrates that, in spite of more than 20 years of 
continuous development, research efforts still leads to the development of original RT inhibitors.  
Figure 10. Proposed model for the mechanism of action for DAVPs and INDOPYs. 
Unlike INDOPYs that are highly specific for the RT/primer-template complex, DAVPs 
also bind unliganded RT, suggesting some differences in the inhibition mechanism of both 
families of compounds. 
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